Access cutting-edge peripheral artery disease treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.
Access peripheral artery disease specialists in Dallas at no cost
This study follows strict safety protocols and ethical guidelines
All study-related peripheral artery disease treatment provided free
A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major amputation, clinically driven target lesion revascularization, and clinically relevant target lesion occlusion after revascularization of lesions below the knee in patients with symptomatic Rutherford 3-5 peripheral artery disease. The primary safety endpoint will be gathered at 1-month post-index procedure. The primar
Sponsor: Mercator MedSystems, Inc.
Check if you qualify for this peripheral artery disease clinical trial in Dallas, TX
If you're searching for peripheral artery disease treatment options in Dallas, TX, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced peripheral artery disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.